BeyondSpring, Inc.
BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. Its lead asset, immuno-oncology agent Plinabulin, is currently in multiple global registration studies, for the prevention of chemotherapy-induced neutropenia and as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
